At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
An open label, phase I/II study to evaluate the safety and efficacy of tenalisib (RP6530), a novel PI3K δ/γ dual inhibitor, given in combination with a histone deacetylase inhibitor, romidepsin, in adult patients with relapsed/refractory T-cell lymphoma.
An open-label, phase 2a/2b study of KRT-232 in subjects with primary myelofibrosis (PMF), post–polycythemia vera MF (post-PV-MF), or post–essential thrombocythemia MF (post–ET-MF) who have failed prior treatment with a JAK inhibitor.
A multicenter, open-label, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of subcutaneous and/or intravenous PF-06741086 in subjects with severe hemophilia A or B.
A double blind, randomized, vehicle controlled, crossover study to evaluate the safety and efficacy of a topical lotion, for the relief of pruritus in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).
A phase III trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-CD22 monoclonal antibody) to frontline therapy in young adults (ages 18-39 years) with newly diagnosed precursor B-cell ALL.